This study is currently not recruiting participants.

A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

Not Recruiting
55 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to determine if oral azacitidine (CC-486) is safe and effective as ?maintenance therapy? in AML treatment and improving the quality of that response.

Detailed description of study

This is an international, multicenter, placebo-controlled, phase 3 study with a double-blind, randomized, parallel-group design with de novo AML (Acute Myeloid Leukemia) or AML secondary to prior diagnosis of Myelodysplastic Syndromes (MDS).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Myeloid Leukemia
  • Age: 55 years - 100 years
  • Gender: All
Updated on 24 Jul 2013. Study ID: 1305011336 (CC-486-AML-00

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team